In 2016, the team at the University of Oxford discovered that alterations in POLE proofreading are ideal biomarkers for recurrence in early-stage colorectal cancer, and these patients have the potential to avoid adjuvant chemotherapy35. This evidence concerns the gene POLE and colorectal cancer.